不同质子泵抑制剂对心脏大血管手术患者围术期应激性溃疡预防的疗效观察及药物经济学评价

详细信息    查看全文 | 推荐本文 |

英文篇名：Therapeutic efficacy and pharmacoeconomic evaluation of different proton pump inhibitor regimens for prevention of perioperative stress ulcer in patients undergoing macrovascular cardiac surgery 作者：王璐 ; 徐航 英文作者：Wang Lu;Xu Hang;Department of Pharmacy, Drum Tower Hospital Affiliated to Nanjing University School of Medicine; 关键词：质子泵抑制剂 ; 应激性溃疡 ; 经济学药物 英文关键词：Proton pump inhibitor;;Stress ulcer;;Economics,pharmaceutieal 中文刊名：YWLC 英文刊名：Chinese Remedies & Clinics 机构：南京大学医学院附属鼓楼医院药学部; 出版日期：2019-05-25 出版单位：中国药物与临床 年：2019 期：v.19 基金：江苏省药学会-奥赛康临床药学基金(201401);; 南京市医学科技发展资金(QRX17060) 语种：中文; 页：YWLC201910005 页数：3 CN：10 ISSN：11-4706/R 分类号：22-24

摘要

目的评价不同质子泵抑制剂对心脏大血管手术患者术后应激性溃疡的预防效果及经济性。方法收集2015年冠状动脉心肌梗死搭桥手术及心脏瓣膜置换手术患者600例,分为奥美拉唑、埃索美拉唑、兰索拉唑组3组,疗程分为1周及2周。观察九组给药方案在3个月内发生消化性溃疡或出血事件情况、死亡情况并应用药物经济学的成本-效果分析法对治疗方案进行经济学评价。结果冠状动脉心肌梗死搭桥患者消化道溃疡发生率高于瓣膜置换患者(P<0.05);不同质子泵抑制剂间消化道溃疡的发生率差异无统计学意义;口服给药低于静脉给药,其中奥美拉唑口服组成本最低,为40.16元。结论质子泵抑制剂能够有效预防心脏大血管手术患者术后应激性溃疡的发生,其中口服给药能够收获与静脉给药同样的效果,并具有较高的经济性。
        Objective To evaluate the therapeuticefficacy and cost-effectiveness of different proton pump inhibitors for prevention of postoperative stress ulcer in patients undergoing macrovascular cardiac surgery. Methods Six hund redpatients undergoing coronary artery bypass or cardiac valve replacement surgery in 2015 were retrospec-tively enrolled in the study and assigned to omeprazole, esomeprazole, and lansoprazole groups. The course of treat-ment was one or two weeks. Nine regimens of these medications were compared for 3-month incidence of peptic ulcer,hemorrhagic events and mortality. Pharmacoeconomics of these regimens was evaluated basedon the cost-effectiveness.Results The incidence rate of pepticulcer in patients undergoing coronary artery bypass grafting was higher com-pared with those undergoing heart valve replacement(P<0.05). There was no significant difference in the incidence of peptic ulcer between different proton pump inhibitor regimens. The medical cost was lower with oral administration than with intravenous administration, and was lowest with oral omeprazol(40.16 yuan RMB). Conclusion: Proton pump inhibitorsmaye ffectively prevent postoperative stress ulcer in patients undergoing macrovascular cardiac surgery. Oral administration of the seagents may offer comparable efficacy as with intravenous administration, meanwhile with better cost-effectiveness.

引文

[1]舒端朝.个体化抗凝方案联合药学监测在人工心脏瓣膜置换术后华法林抗凝治疗中的应用效果[J].实用心脑肺血管病杂志,2015,23(11):123-125.
    [2]秦春妮,黑飞龙.体外循环心脏术后消化系统并发症的防治进展[J].世界华人消化杂志, 2012,45(15):1318-1322.
    [3]杨省利,郭文怡,朱琦霞,等.冠心病介入治疗患者上消化道出血并发症的干预研究[J].心脏杂志,2013,25(4):509.
    [4]宋现涛,吕树铮,陈韵岱,等.经皮冠状动脉介入治疗后患者住院期间合并上消化道出血分析[J].中华心血管病杂志,2007, 35(4):308-311.
    [5]匡霞,张先翠. ICU危重病人应激性溃疡的预防及护理进展[J].护理研究,2008,8(22):1977-1979.
    [6]朱丽萍,黄毅婷,庄捷.外科手术预防使用质子泵抑制剂的分析与评价[J].海峡药学, 2013, 25(11):127-128.
    [7]柏蓉,张晓兰,鲍丽琴,等.制定注射用质子泵抑制剂药物利用评价标准评析预防应激性溃疡用药的合理性[J].药学与临床研究,2016,24(6):472-474.
    [8]吴明杰.住院患者注射用质子泵抑制剂不合理应用分析[J].中国医院用药评价与分析, 2016, 16(2):257-259.
    [9]张艳玲.心脏直视手术患者术后应激性溃疡的防治概述[J].中国药业, 2014, 23(8):89-91.
    [10]吕小娟,艾伟鹏,马林.质子泵抑制剂预防危重症患者并发应激性溃疡的循证药物经济学评价[J].中国医院药学杂志,2015,35(24):2237-2240.
    [11]邢晓璇,白向荣,褚燕琦,等.围术期住院患者应用抑酸药预防应激性溃疡效果回顾性分析[J].临床药物治疗杂志, 2018,16(1):55-60.
    [12]李菁,李荣东.质子泵抑制剂的研究进展[J].儿科药学杂志,2014,20(4):61-64.
    [13]袁田伟,徐联政.奥美拉唑与兰索拉唑预防危重病并发应激性溃疡的疗效及成本-效果分析[J].长沙医学院学报,2015,13(1):7-9.
    [14]卢年芳,郑瑞强,林华,等.国产泮托拉唑与进口奥美拉唑预防应激性溃疡的疗效及成本效果分析[J].中国新药与临床杂志,2007,26(4):295-298.